Haematology

Santa Maria Nuova, Italy

Haematology

Santa Maria Nuova, Italy
SEARCH FILTERS
Time filter
Source Type

LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to the NuPreviq Approach. Data from the NuPreviq study (GENA-21, NCT01863758) were published online in April 2017 as an Early View article in the internationally renowned medical journal, Haemophilia. The NuPreviq study was initiated in August 2013 with the aim of developing a fully personalized service for HA patients undergoing prophylactic therapy. Octapharma’s aim is to improve patient treatment experiences by recognizing that no two HA patients are the same, therefore a “one size fits all” approach to prophylaxis is not ideal. The NuPreviq study investigated a novel approach, allowing the Nuwiq® treatment regimen to be adapted to the specific needs of each individual patient. The NuPreviq Approach measures and profiles each individual patient’s pharmacokinetic response to treatment, which then allows the dosing of Nuwiq® to be personalized according to the specific circumstances of that patient. The results of the study showed that this personalized prophylaxis approach was very effective at preventing bleeds, while reducing the frequency of dosing and the amount of Nuwiq® needed. Over 80% of patients did not experience a spontaneous bleed during the 6 months of personalized prophylaxis with Nuwiq®. More than half of the patients received infusions twice a week or less, and dose requirements were reduced by 7%. An ongoing extension study (GENA-21b, NCT02256917) will further evaluate the long-term efficacy and safety of personalized prophylaxis with Nuwiq®. Larisa Belyanskaya, Head of IBU Haematology at Octapharma, said: “We are very excited by the results of the NuPreviq study and pleased that the GENA-21 study data are now available to the wider public in the specialist peer-reviewed publication, Haemophilia. The study shows that personalized prophylaxis with Nuwiq® provides excellent bleeding protection, extension of the dosing interval for most patients, and a reduction in dose. These data further differentiate Nuwiq® from other products on the market.” Olaf Walter, Board Member at Octapharma, commented that “Octapharma’s principal motivation lies with providing dedicated service to our patients. Developing a custom care package which offers flexible FVIII therapy, truly personalized to suit their needs and lifestyle, has long been a goal of the company and we celebrate today this landmark publication of the extremely positive NuPreviq clinical data.” Octapharma would like to thank everyone involved in the study, in particular the patients and their families, without whom this research would not be possible. About GENA-21 and GENA-21b studies: The GENA-21 and GENA-21b studies, initiated in August 2013 and March 2015, respectively, are prospective, open-label, multicentre, Phase 3b studies assessing the safety and efficacy of PK-guided personalized prophylaxis with Nuwiq® in previously treated adult patients with severe HA. The studies are each conducted across 29 study locations worldwide. About Nuwiq®: Nuwiq® is a naturally long-acting, 4th generation rFVIII protein, produced in a human cell line without chemical modification or fusion with any other protein. Nuwiq® is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 PTPs (190 individuals) with severe HA, including 59 children. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding across all age groups of PTPs with haemophilia A in the EU, US, Canada, Australia, Latin America and Russia. Further worldwide submissions for Nuwiq® are planned. About haemophilia A: Haemophilia A is an X-linked hereditary disorder caused by FVIII deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This disorder affects one in every 5,000 to 10,000 men worldwide. Globally, 75% of haemophilia cases are left undiagnosed or untreated. The development of neutralizing FVIII antibodies (FVIII inhibitors) against infused FVIII represents the most serious treatment complication. The cumulative risk of FVIII inhibitor development is reported to be currently up to 39%. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. In 2016, the Group achieved €1.6 billion in revenue, an operating income of €383 million and invested €249 million to ensure future prosperity. Octapharma employs more than 7,100 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas: Octapharma owns six state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.


LACHEN, Suíça--(BUSINESS WIRE)--A Octapharma anunciou novos dados clínicos positivos em 66 pacientes com hemofilia A (HA) grave tratados previamente (PTPs) submetidos à profilaxia personalizada orientada por PK com Nuwiq® de acordo com o Método NuPreviq. Os dados do estudo NuPreviq (GENA-21, NCT01863758) foram publicados on-line em abril de 2017 como um artigo Early View na revista médica de renome internacional Haemophilia. O estudo NuPreviq foi iniciado em agosto de 2013 com o objetivo de desenvolver um serviço totalmente personalizado para pacientes com HA submetidos à terapia profilática. O objetivo da Octapharma é melhorar as experiências de tratamento do paciente, reconhecendo que nenhum paciente com HA é igual, portanto, uma “abordagem única para todos” para a profilaxia não é ideal. O estudo NuPreviq investigou uma nova abordagem, permitindo que o regime de tratamento do Nuwiq® fosse adaptado às necessidades específicas de cada paciente. O Método NuPreviq mede e perfila a resposta farmacocinética de cada paciente ao tratamento, o que permite que a dose de Nuwiq® seja personalizada de acordo com as circunstâncias específicas desse paciente. Os resultados do estudo mostraram que esta abordagem de profilaxia personalizada foi muito eficaz na prevenção de hemorragias, reduzindo a frequência da dose e a quantidade necessária de Nuwiq®. Mais de 80% dos pacientes não apresentaram hemorragia espontânea durante os seis meses de profilaxia personalizada com Nuwiq®. Mais de metade dos pacientes receberam infusões duas vezes por semana – ou menos – e os requisitos de dose foram reduzidos em 7%. Um estudo de extensão em andamento (GENA-21b, NCT02256917) irá avaliar ainda mais a eficácia e a segurança a longo prazo da profilaxia personalizada com Nuwiq®. Larisa Belyanskaya, chefe de IBU Haematology na Octapharma, disse: “Estamos muito entusiasmados com os resultados do estudo NuPreviq e satisfeitos que os dados do estudo GENA-21 que agora estão disponíveis ao público em geral na revista especializada Haemophilia. O estudo mostra que a profilaxia personalizada com Nuwiq® proporciona excelente proteção contra a hemorragia, extensão do intervalo de dose para a maioria dos pacientes e redução da dose. Esses dados diferenciam ainda mais o Nuwiq® de outros produtos no mercado.” Olaf Walter, membro do conselho da Octapharma, comentou que “a principal motivação da Octapharma está na prestação de serviço dedicado aos pacientes. Desenvolver um pacote de cuidados customizados que oferece uma terapêutica flexível de FVIII, verdadeiramente personalizado para atender às necessidades e estilo de vida do paciente, tem sido um objetivo da empresa e hoje podemos comemorar esta publicação dos dados clínicos extremamente positivos do NuPreviq”. Sobre os estudos GENA-21 e GENA-21b: Os estudos GENA-21 e GENA-21b, com início em agosto de 2013 e março de 2015, respectivamente, são estudos prospectivos, abertos, multicêntricos, de Fase 3b que avaliam a segurança e a eficácia da profilaxia personalizada orientada por PK com Nuwiq® em pacientes adultos com HA grave tratados previamente. Os estudos são realizados em 29 locais de estudo no mundo todo. Sobre o Nuwiq®: O Nuwiq® é uma proteína rFVIII de 4a geração, de ação natural, de longa duração, produzida em uma linha celular humana sem modificação química ou fusão com qualquer outra proteína. O Nuwiq® é cultivada sem aditivos de origem humana ou animal, é desprovida de epítopos antigênicos de proteínas não humanas e tem uma elevada afinidade para o fator de coagulação de von Willebrand. A terapêutica com Nuwiq® foi avaliada em sete ensaios clínicos concluídos que incluíram 201 pacientes tratados previamente (190 indivíduos) com HA grave, incluindo 59 crianças. O Nuwiq® é aprovado para uso no tratamento e profilaxia do sangramento em todas as faixas etárias de pacientes tratados previamente com hemofilia A na União Europeia, EUA, Canadá, Austrália, América Latina e Rússia. Outras propostas mundiais para o Nuwiq® estão sendo planejadas. Sobre a Hemofilia A: A hemofilia A é uma doença hereditária ligada ao cromossomo X causada pela deficiência de FVIII que, se não tratada, provoca hemorragias nos músculos e articulações e, consequentemente, artropatia e morbidade grave. O tratamento profilático de reposição do FVIII reduz o número de episódios de sangramento e o risco de lesões articulares permanentes. Este distúrbio afeta um em cada 5 mil a 10 mil homens em todo o mundo e 75% dos casos de hemofilia não são diagnosticados ou tratados. O desenvolvimento de anticorpos que neutralizam o FVIII (inibidores do FVIII) contra o FVIII injetado representa a complicação mais séria do tratamento. O risco cumulativo de desenvolvimento de inibidores do FVIII é de até 39% dos casos. Com sede em Lachen, Suíça, a Octapharma é uma das maiores fabricantes de proteína humana no mundo, desenvolvendo e produzindo proteínas humanas a partir do plasma humano e linhas de células humanas. Como uma empresa familiar, a Octapharma acredita no investimento para fazer diferença nas vidas das pessoas – e vem fazendo isto desde 1983, pois está no nosso sangue. O texto no idioma original deste anúncio é a versão oficial autorizada. As traduções são fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que é a única versão do texto que tem efeito legal.


News Article | May 4, 2017
Site: news.europawire.eu

More than 3,000 medical laboratory industry professionals expected to attend the launch edition of MEDLAB Europe at the Barcelona Congress Centre in Spain Barcelona, Spain, 04-May-2017 — /EuropaWire/ — After many years of operating successful MEDLAB events around Africa, Asia and the Middle East, Informa Life Sciences Exhibitions, the worlds leading publishing and exhibitions company, has announced that the MEDLAB Series will be expanding its presence into Europe. Taking place at the Barcelona Congress Centre in Barcelona, Spain, from 13-15 September 2017, more than 3,000 industry professionals are expected to attend Europe’s leading event for laboratory management and diagnosis. With the European In-Vitro Diagnostics (IVD) market expected to reach USD 15.5 billion by 2024, a platform such as MEDLAB presents a huge opportunity for global laboratory industry leaders, including manufacturers, dealers and distributors, to make inroads into the European market. Housing international exhibitors and covering 2,000 sqm of exhibition space, MEDLAB Europe will give visitors from across the world an opportunity to access cutting-edge laboratory products, next-generation technology, innovative services and world-class educational content. According to Tom Coleman, Group Exhibition Director, MEDLAB Series: “The launch of MEDLAB Europe is in line with our global expansion strategy for our MEDLAB series of events. The increasing prevalence of chronic diseases, rising geriatric population coupled with the rising awareness towards early diagnosis, has positioned the European IVD and medical laboratory market as a critical market for manufacturers, services providers, and dealers and distributors from across the globe. MEDLAB Europe will generate substantial value for our customers and partners by driving further product innovation and deeper engagement in these specific markets.” Over the four-day event, MEDLAB Europe will also offer a multi-disciplinary congress tackling current challenges and developments key to the European market, and leveraging the true potential of laboratory testing to dramatically improve patient outcomes across the continent. The conference programme covers five main tracks including Point of Care Testing (POCT), Histopathology, Lab Management, Microbiology and Haematology. From new methods of effective lab management to the development of techniques in detecting diseases, the conferences will also review the expanding role of the laboratory medicine and discuss partnership between a clinician and a lab professional in providing delivery of care to every patient. “The scientific programme at MEDLAB has been carefully designed in collaboration with some of the brightest minds in the medical laboratory industry in order to have a real impact on improving the health and wellbeing of patients across the region,” said Coleman. For more information about the MEDLAB Europe Exhibition & Congress, please visit: www.medlabeurope.com.


News Article | May 4, 2017
Site: www.24-7pressrelease.com

BARCELONA, SPAIN, May 04, 2017-- After many years of operating successful MEDLAB events around Africa, Asia and the Middle East, Informa Life Sciences Exhibitions, the worlds leading publishing and exhibitions company, has announced that the MEDLAB Series will be expanding its presence into Europe. Taking place at the Barcelona Congress Centre in Barcelona, Spain, from 13-15 September 2017, more than 3,000 industry professionals are expected to attend Europe's leading event for laboratory management and diagnosis With the European In-Vitro Diagnostics (IVD) market expected to reach USD 15.5 billion by 2024 , a platform such as MEDLAB presents a huge opportunity for global laboratory industry leaders, including manufacturers, dealers and distributors, to make inroads into the European market. Housing international exhibitors and covering 2,000 sqm of exhibition space, MEDLAB Europe will give visitors from across the world an opportunity to access cutting-edge laboratory products, next-generation technology, innovative services and world-class educational content.According to Tom Coleman, Group Exhibition Director, MEDLAB Series: "The launch of MEDLAB Europe is in line with our global expansion strategy for our MEDLAB series of events. The increasing prevalence of chronic diseases, rising geriatric population coupled with the rising awareness towards early diagnosis, has positioned the European IVD and medical laboratory market as a critical market for manufacturers, services providers, and dealers and distributers from across the globe. MEDLAB Europe will generate substantial value for our customers and partners by driving further product innovation and deeper engagement in these specific markets."Over the four-day event, MEDLAB Europe will also offer a multi-disciplinary congress tackling current challenges and developments key to the European market, and leveraging the true potential of laboratory testing to dramatically improve patient outcomes across the continent.The conference programme covers five main tracks including Point of Care Testing (POCT), Histopathology Microbiology and Haematology . From new methods of effective lab management to the development of techniques in detecting diseases, the conferences will also review the expanding role of the laboratory medicine and discuss partnership between a clinician and a lab professional in providing delivery of care to every patient."The scientific programme at MEDLAB has been carefully designed in collaboration with some of the brightest minds in the medical laboratory industry in order to have a real impact on improving the health and wellbeing of patients across the region," said Coleman.For more information about the MEDLAB Europe Exhibition & Congress, please visit: www.medlabeurope.com Informa Life Sciences Exhibitions, in charge of the healthcare portfolio within Informa's Global Exhibitions division, organises 26 exhibitions yearly covering the Middle East, Africa, Asia, Europe and US market, connecting more than 150,000 healthcare professionals worldwide and offering a range of marketing solutions for companies involved with the healthcare sector. Over 100 congresses take place in parallel with the exhibitions.Informa Life Sciences Exhibitions publishes four international healthcare magazines, offers Dothealth, a healthcare portal showcasing over 40,000 healthcare companies and runs Healthy Change, an online recruitment portal.


News Article | April 27, 2017
Site: www.eurekalert.org

Research led by University of Leicester and University Hospitals of Leicester NHS Trust reveals 'transformative outcomes' for patients with chronic lymphocytic leukemia "We are proud to be part of this study. Our long term follow up of previously treated patients shows maintained efficacy without toxicity. This study is the first report of long term follow-up of selective BTK inhibitors in patients with chronic lymphocytic leukaemia - and it is excellent news for patients." Scientists have described new results of a blood cancer study as 'outstanding' in tackling previously untreatable forms of chronic lymphocytic leukaemia (CLL). The advance led by a team from the University of Leicester and University Hospitals of Leicester NHS Trust, within the Hope Clinical Trials Facility, focused on treating patients with CLL. It follows on from a world-first clinical trial of a new drug to treat particular blood cancers. Results of that international clinical trial, led by Dr Harriet Walter and Professor Martin Dyer were published in the journal Blood in November 2015 and looked at the efficacy of a new inhibitor, ONO/GS-4059, in the treatment of CLL and Non-Hodgkin Lymphoma patients, refractory or resistant to current chemotherapies. ONO/GS-4059 targets BTK, a protein essential for the survival and proliferation of the tumour cells. The study opened in January 2012 and 90 patients were enrolled in different centres in the UK and in France, with 28 coming from Leicester. Patients with CLL showed the best response and most of them were still on the study after 3 years, and remarkably without notable toxicities. In the new paper, the researchers are reporting for the long-term follow-up results. Their work, published in the journal Blood, was funded by the Ernest and Helen Scott Haematological Research Institute, ONO Pharmaceuticals, Gilead Pharmaceuticals and the Cancer Research UK Leicester Experimental Cancer Medicine Centre. Local charity Hope Against Cancer fund the Clinical Trials Facility based at the Leicester Royal Infirmary. Professor Martin Dyer is Professor of Haemato-Oncology in the Department of Cancer Studies at the University of Leicester and Honorary Consultant Physician in the Department of Haematology at Leicester Royal Infirmary. He said: "This current paper describes the long term follow up and shows that in patients with CLL the remissions are durable and associated with no new toxicities. Furthermore, in collaboration with Sistemas Genomicos, a company in Valencia, we have shown that mutations associated with aggressive disease respond well to treatment with ONO/GS-4059. "Our long term follow up shows maintained efficacy without toxicity. This study is the first report of long term follow-up of a selective BTK inhibitor - and it is excellent news for patients. "The results we are presenting are based on an international clinical study involving the UK, France, Japan and US - and led by Leicester. This was a Phase 1 clinical study which means the researchers are in the early stages of testing the drug's effectiveness. "We are now doing studies of ONO/GS-4059 in combination with other precision medicines to assess whether these results can be enhanced in patients with CLL and other B cell malignancies." Local cancer research charity, Hope Against Cancer, has been funding some of Professor Dyer's work. Chief Executive of the charity, Nigel Rose said: "Professor Dyer is a long-standing collaborator and recipient of Hope's funding. We are delighted that this is being put to such extremely important use in meeting our charity's mission of improving the lives of cancer patients locally."


Professor Mersburger, who joined the European Oncology & Haematology Editorial Board last year, will become the first Editor-in-Chief of the journal. "It is a great honour and privilege to support European Oncology and Haematology as Editor-in-Chief. The Journal is delivered in two print issues per year (summer & winter), which gives the latest developments in haematology and oncology, as well as ePub ahead of print throughout the year. It is exciting to work with the international, multidisciplinary editorial board providing you the recent developments in their field. The journal will further invest in including up-to-date, high-quality, and original contributions - research papers, as well as reviews, and conference reviews," said Merseburger following his appointment. Professor Merseburger is Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany. He is a member of the European Association of Urology (EAU) Guideline Group for Renal Cancer and Chairman of the EAU Guideline Group for Lasers and Technologies. Professor Merseburger has won multiple awards, stipends and prizes for his molecular and clinical research and has published more than 150 papers in peer-reviewed journals. His main area of interest is urological oncology. Professor Merseburger's key areas of interest are renal cell carcinoma, prostate cancer and transitional cell carcinoma, with special attention given to novel markers and prognostic factors. He is a principal investigator in German Phase II and III trials. European Oncology & Hameatology was launched in 2007 and specialises in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of oncology. "It is an honour to name Axel Merseburger as the Editor-in-Chief of European Oncology & Haematology," said Barney Kent, Managing Director of Touch Medical Media. "I know Prof. Merseburger is keen to develop the journal in a number of ways so we are really excited to have him involved at this level and are looking forward to working with him over the coming years." touchONCOLOGY (a division of Touch Medical Media) publishesEuropean Oncology & Haematology Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of oncology and haematology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals. Touch Medical Media is a trading name of Touch Digital Media Limited, a private limited company registered in England and Wales at The White House Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. Leading the Debate on the Advances in Healthcare .


News Article | May 23, 2017
Site: www.eurekalert.org

A study led by the University of Birmingham has made a breakthrough in the understanding of how different genetic mutations cause acute myeloid leukaemia. One of the most common acute leukaemia's in adults with around 2,400 people in the UK diagnosed with the disease each year, the survival rates for those diagnosed with acute myeloid leukaemia are very poor and new treatments are needed. Researchers at the Universities of Birmingham and Newcastle worked in collaboration to study the DNA of two types of acute myeloid leukaemia in an effort to explain how clinical prognosis can differ. Professor Constanze Bonifer, of the Institute of Cancer and Genomic Sciences at the University of Birmingham, said: "Is has been known for a long time that acute myeloid leukaemia is highly heterogeneous, involving different disease-causing genetic mutations. "This in turn leads to highly variable clinical outcomes, with some patients responding better to certain treatments than others. "Prior to this study, the reason for the differences in response to treatment was unknown. "We discovered how two closely related oncogenes - genes which have the potential to cause cancer - differently reprogram blood stem cells in acute myeloid leukaemia and send them spiralling out of control." The study, published today in Cell Reports, highlights the difficulties faced in understanding the heterogeneity of the disease. Dr Justin Loke, a Kay Kendall Clinical Fellow from Birmingham Queen Elizabeth Hospital's Haematology Department which is affiliated with the University of Birmingham's Institute of Cancer and Genomic Sciences, added: "We used state-of-the-art molecular technology that studies all genes within leukaemic cells to investigate why two types of the disease with mutations in the same gene display a completely different clinical profile. "We showed that the maintenance of the leukaemic state of these two types of acute myeloid leukaemia is dependent on different sets of normal genes, therefore identifying a route to developing tailored and personalized treatments for patients with different cancer-causing mutations in order to specifically target each tumour." Since the early 1990s, acute myeloid leukaemia incidence rates have increased by more than a quarter (28 per cent) in the UK. One in 200 men and one in 255 women will be diagnosed with acute myeloid leukaemia during their lifetime. The study was funded by the Kay Kendall Leukaemia Fund and Bloodwise. Bloodwise, the UK's specialist blood cancer charity, funds world-class research and offers expert information and support to anyone affected by leukaemia, lymphoma, myeloma and other blood cancer related disorders. The Kay Kendall Leukaemia Fund was established in 1984 under the Will of the late James Sainsbury CBE. It awards grants for research on aspects of leukaemia and for relevant studies on related haematological malignancies. For further information or interviews contact: Emma McKinney, Press Office, University of Birmingham, at 0121 414 6681 or e.j.mckinney@bham.ac.uk


News Article | May 25, 2017
Site: www.sciencedaily.com

A study led by the University of Birmingham has made a breakthrough in the understanding of how different genetic mutations cause acute myeloid leukemia. One of the most common acute leukemia's in adults with around 2,400 people in the UK diagnosed with the disease each year, the survival rates for those diagnosed with acute myeloid leukemia are very poor and new treatments are needed. Researchers at the Universities of Birmingham and Newcastle worked in collaboration to study the DNA of two types of acute myeloid leukemia in an effort to explain how clinical prognosis can differ. Professor Constanze Bonifer, of the Institute of Cancer and Genomic Sciences at the University of Birmingham, said: "Is has been known for a long time that acute myeloid leukemia is highly heterogeneous, involving different disease-causing genetic mutations. "This in turn leads to highly variable clinical outcomes, with some patients responding better to certain treatments than others. "Prior to this study, the reason for the differences in response to treatment was unknown. "We discovered how two closely related oncogenes -- genes which have the potential to cause cancer -- differently reprogram blood stem cells in acute myeloid leukemia and send them spiralling out of control." The study, published today in Cell Reports, highlights the difficulties faced in understanding the heterogeneity of the disease. Dr Justin Loke, a Kay Kendall Clinical Fellow from Birmingham Queen Elizabeth Hospital's Haematology Department which is affiliated with the University of Birmingham's Institute of Cancer and Genomic Sciences, added: "We used state-of-the-art molecular technology that studies all genes within leukaemic cells to investigate why two types of the disease with mutations in the same gene display a completely different clinical profile. "We showed that the maintenance of the leukaemic state of these two types of acute myeloid leukemia is dependent on different sets of normal genes, therefore identifying a route to developing tailored and personalized treatments for patients with different cancer-causing mutations in order to specifically target each tumour." Since the early 1990s, acute myeloid leukemia incidence rates have increased by more than a quarter (28 per cent) in the UK. One in 200 men and one in 255 women will be diagnosed with acute myeloid leukemia during their lifetime.


Professor Mersburger, who joined the European Oncology & Haematology Editorial Board last year, will become the first Editor-in-Chief of the journal. "It is a great honour and privilege to support European Oncology and Haematology as Editor-in-Chief. The Journal is delivered in two print issues per year (summer & winter), which gives the latest developments in haematology and oncology, as well as ePub ahead of print throughout the year. It is exciting to work with the international, multidisciplinary editorial board providing you the recent developments in their field. The journal will further invest in including up-to-date, high-quality, and original contributions - research papers, as well as reviews, and conference reviews," said Merseburger following his appointment. Professor Merseburger is Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany. He is a member of the European Association of Urology (EAU) Guideline Group for Renal Cancer and Chairman of the EAU Guideline Group for Lasers and Technologies. Professor Merseburger has won multiple awards, stipends and prizes for his molecular and clinical research and has published more than 150 papers in peer-reviewed journals. His main area of interest is urological oncology. Professor Merseburger's key areas of interest are renal cell carcinoma, prostate cancer and transitional cell carcinoma, with special attention given to novel markers and prognostic factors. He is a principal investigator in German Phase II and III trials. European Oncology & Hameatology was launched in 2007 and specialises in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of oncology. "It is an honour to name Axel Merseburger as the Editor-in-Chief of European Oncology & Haematology," said Barney Kent, Managing Director of Touch Medical Media. "I know Prof. Merseburger is keen to develop the journal in a number of ways so we are really excited to have him involved at this level and are looking forward to working with him over the coming years." touchONCOLOGY (a division of Touch Medical Media) publishesEuropean Oncology & Haematology Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of oncology and haematology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals. Touch Medical Media is a trading name of Touch Digital Media Limited, a private limited company registered in England and Wales at The White House Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. Leading the Debate on the Advances in Healthcare .


L'étude NuPreviq a débuté en août 2013 avec pour objectif de développer un service totalement personnalisé pour les patients HA traités par prophylaxie. Le but d'Octapharma vise à améliorer les traitements des patients, en reconnaissant qu'il n'y a pas deux patients HA identiques, l'approche "dose unique" de la prophylaxie n'étant donc pas idéale. L'étude NuPreviq a étudié une nouvelle approche, permettant d'adapter le rythme du traitement Nuwiq® aux besoins spécifiques et individuels de chaque patient. L'approche NuPreviq mesure et établit le profil de la réponse pharmacocinétique individuelle de chaque patient au traitement, permettant de personnaliser la dose de Nuwiq® en fonction des caractéristiques du chacun. Les résultats de l'étude ont montré que l'approche personnalisée de cette prophylaxie était très efficace pour éviter les saignements, tout en réduisant la fréquence des injections et le nombre d’unités de Nuwiq® nécessaires. Plus de 80% des patients n'ont pas eu de saignement spontané au cours des 6 mois de prophylaxie personnalisée avec Nuwiq®. Plus de la moitié des patients ont reçu des injections deux fois par semaine ou moins, et la dose requise a été réduite de 7%. L'évaluation de l'efficacité à long-terme avec Nuwiq® se poursuit (GENA-21b, NCT02256917) ainsi que l’évaluation de la tolérance de la prophylaxie personnalisée. Larisa Belyanskaya, Head of IBU Haematology Octapharma, a déclaré : “Nous sommes particulièrement satisfaits des résultats de l'étude NuPreviq et nous nous réjouissons que les données de l'étude GENA-21 soient désormais accessibles à un plus large public dans un article publiédans Haemophilia. L'étude montre que la prophylaxie personnalisée avec Nuwiq® fournit une excellente protection contre les saignements, un allongement de l'intervalle des injections chez la plupart des patients, ainsi qu'une réduction de la dose. Ces données différentient davantage Nuwiq® par rapport aux autres produits du marché.” Olaf Walter, Board Member Octapharma, a rajouté que “la principale motivation d'Octapharma est d'offrir des services spécialisés à nos patients. Le développement d'une formule de « soins sur mesure » offrant un traitement par FVIII flexible et réellement personnalisé aux besoins et au mode de vie du patient, a toujours été un objectif pour la compagnie et nous célébrons aujourd'hui la publication capitale de données cliniques extrêmement positives du NuPreviq.” À propos des études GENA-21 et GENA-21b : Les études GENA-21 et GENA-21b, lancées respectivement en août 2013 et en mars 2015, sont des études prospectives, ouvertes, multicentriques de phase IIIb, évaluant la sécurité et l'efficacité de la prophylaxie personnalisée basée sur l'analyse PK avec Nuwiq® chez les patients adultes précédemment traités pour HA sévère. Les deux études sont menées sur 29 sites dans le monde. À propos de Nuwiq® : Nuwiq® est un concentré de FVIII recombinant de 4ème génération, produit dans des cellules humaines sans modification chimique ni fusion de protéines. Nuwiq® est fabriqué sans additif d'origine humaine ou animale, est dépourvu d'épitopes de protéine antigénique non-humaine et montre une grande affinité pour le facteur de coagulation von Willebrand. Nuwiq® a été évalué lors de sept essais cliniques terminés impliquant 201 PPT (190 individus) atteints de HA sévère, dont 59 enfants. L'utilisation de Nuwiq® est approuvée dans le traitement et la prophylaxie de saignements dans tous les groupes d'âge de PPT atteints d'hémophilie A dans l'UE, aux Etats-Unis, au Canada, en Australie, en Amérique Latine et en Russie. D'autres soumissions de Nuwiq® sont prévues dans le monde. À propos de l'hémophilie A : L'hémophilie A est une maladie héréditaire liée au chromosome X, provoquée par un déficit en facteur VIII et qui, en l'absence de traitement, conduit à des hémorragies dans les muscles et les articulations, puis à une arthropathie et à une morbidité grave. Le traitement prophylactique substitutif par facteur VIII permet de réduire le nombre d'épisodes hémorragiques ainsi que le risque de dommages articulaires permanents. Cette maladie touche un homme sur 5 000 à 10 000 à travers le monde. Dans le monde, 75 % des patients hémophiles ne sont ni diagnostiqués ni traités. Le développement d’anticorps neutralisants (inhibiteurs) dirigés contre le facteur VIII injecté est la complication la plus grave. Actuellement, l’incidence cumulative du risque de développement d’inhibiteur peut atteindre jusqu’ à 39 %. Octapharma, dont le siège social se situe à Lachen, en Suisse, est l'un des plus importants fabricants de médicaments à base de protéines humaines au monde. Il développe et produit des protéines humaines à partir de plasma humain et de lignées cellulaires humaines. Persuadée que les investissements sont en mesure d’améliorer la vie des patients, la société familiale Octapharma s’y consacre depuis 1983 ; car c’est dans notre sang.

Loading Haematology collaborators
Loading Haematology collaborators